JPWO2019224711A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019224711A5 JPWO2019224711A5 JP2020564908A JP2020564908A JPWO2019224711A5 JP WO2019224711 A5 JPWO2019224711 A5 JP WO2019224711A5 JP 2020564908 A JP2020564908 A JP 2020564908A JP 2020564908 A JP2020564908 A JP 2020564908A JP WO2019224711 A5 JPWO2019224711 A5 JP WO2019224711A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- polypeptide sequence
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 256
- 239000000427 antigen Substances 0.000 claims description 82
- 102000038129 antigens Human genes 0.000 claims description 82
- 108091007172 antigens Proteins 0.000 claims description 82
- 102000004965 antibodies Human genes 0.000 claims description 50
- 108090001123 antibodies Proteins 0.000 claims description 50
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 35
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 210000004027 cells Anatomy 0.000 claims description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102100016493 CD33 Human genes 0.000 claims description 11
- 101700017647 CD33 Proteins 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 201000005787 hematologic cancer Diseases 0.000 claims description 10
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 8
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 8
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 4
- 102000002110 C2 domain Human genes 0.000 claims description 4
- 108050009459 C2 domain Proteins 0.000 claims description 4
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 4
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010025310 Other lymphomas Diseases 0.000 claims description 4
- 210000002381 Plasma Anatomy 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 201000009251 multiple myeloma Diseases 0.000 claims description 4
- 108010071919 Bispecific Antibodies Proteins 0.000 claims description 2
- 230000036947 Dissociation constant Effects 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 201000009030 carcinoma Diseases 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 230000001419 dependent Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002489 hematologic Effects 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 4
- 206010058314 Dysplasia Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676123P | 2018-05-24 | 2018-05-24 | |
| US62/676,123 | 2018-05-24 | ||
| US201962825846P | 2019-03-29 | 2019-03-29 | |
| US62/825,846 | 2019-03-29 | ||
| PCT/IB2019/054182 WO2019224711A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524244A JP2021524244A (ja) | 2021-09-13 |
| JPWO2019224711A5 true JPWO2019224711A5 (ru) | 2022-05-25 |
Family
ID=67211770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564908A Pending JP2021524244A (ja) | 2018-05-24 | 2019-05-21 | 抗ｃｄ３３抗体、抗ｃｄ３３／抗ｃｄ３二重特異性抗体、及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11466082B2 (ru) |
| EP (1) | EP3802606A2 (ru) |
| JP (1) | JP2021524244A (ru) |
| KR (1) | KR20210013156A (ru) |
| CN (1) | CN112189022A (ru) |
| AU (1) | AU2019274229A1 (ru) |
| BR (1) | BR112020023357A2 (ru) |
| CA (1) | CA3101270A1 (ru) |
| CL (1) | CL2020003028A1 (ru) |
| CO (1) | CO2020014575A2 (ru) |
| CR (1) | CR20200567A (ru) |
| EC (1) | ECSP20075198A (ru) |
| IL (1) | IL278844A (ru) |
| JO (1) | JOP20190116A1 (ru) |
| MA (1) | MA52771A (ru) |
| MX (1) | MX2020012588A (ru) |
| NI (1) | NI202000088A (ru) |
| PE (1) | PE20210180A1 (ru) |
| PH (1) | PH12020552010A1 (ru) |
| SG (1) | SG11202011210TA (ru) |
| TW (1) | TW202033551A (ru) |
| UY (1) | UY38242A (ru) |
| WO (1) | WO2019224711A2 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015380A (es) | 2015-05-29 | 2018-03-28 | Amphivena Therapeutics Inc | Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33. |
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| DE102018127845A1 (de) | 2018-11-07 | 2020-05-07 | Grimme Landmaschinenfabrik Gmbh & Co. Kg | Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten |
| MX2021009975A (es) * | 2019-02-22 | 2021-12-10 | Memorial Sloan Kettering Cancer Center | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. |
| IL293670A (en) * | 2019-12-09 | 2022-08-01 | Twist Bioscience Corp | Variable nucleic acid libraries for adenosine receptors |
| KR20220154728A (ko) * | 2020-03-13 | 2022-11-22 | 얀센 바이오테크 인코포레이티드 | Siglec-3/cd33을 결합시키기 위한 물질 및 방법 |
| EP4126245A4 (en) * | 2020-03-31 | 2024-05-08 | Fred Hutchinson Cancer Center | ANTI-CD33 ANTIBODIES AND THEIR USES |
| US11919944B2 (en) | 2020-05-11 | 2024-03-05 | Augmenta Biosciences, Inc. | Antibodies for SARS-CoV-2 and uses thereof |
| WO2022060901A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| US20220259319A1 (en) * | 2021-01-21 | 2022-08-18 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| TW202302636A (zh) | 2021-02-16 | 2023-01-16 | 比利時商健生藥品公司 | 靶向ｂｃｍａ、ｇｐｒｃ５ｄ及ｃｄ３之三特異性抗體 |
| WO2022200443A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Pharmaceutica Nv | TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3 |
| WO2022228471A1 (zh) * | 2021-04-27 | 2022-11-03 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| WO2023006118A1 (en) * | 2021-07-30 | 2023-02-02 | Nanjing Legend Biotech Co., Ltd. | Anti-cd33 antibodies and uses thereof |
| CA3228414A1 (en) * | 2021-09-02 | 2023-03-09 | Anthony DANIYAN | Anti-cd33 antibodies and uses thereof |
| TW202328193A (zh) * | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
| WO2023081898A1 (en) * | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUE026914T2 (en) | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| JP5686953B2 (ja) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用 |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| NZ580755A (en) | 2007-04-03 | 2012-05-25 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| SI2352763T2 (sl) | 2008-10-01 | 2022-11-30 | Amgen Research (Munich) Gmbh | Bispecifična enoverižna protitelesa s specifičnostjo za tarčne antigene z visoko molekulsko maso |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| SI2356153T1 (sl) | 2008-10-01 | 2016-07-29 | Amgen Research (Munich) Gmbh | Bispecifično enoverižno protitelo, specifično za križane vrste |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| BR112012026766B1 (pt) | 2010-04-20 | 2021-11-03 | Genmab A/S | Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| KR102239125B1 (ko) | 2012-12-14 | 2021-04-12 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 인간 이디오타입을 갖는 설치류 항체를 인코딩하는 폴리뉴클레오티드 및 이를 포함하는 동물 |
| TWI688401B (zh) * | 2013-09-13 | 2020-03-21 | 美商安進公司 | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 |
| EA201691214A1 (ru) | 2013-12-13 | 2016-12-30 | Дженентек, Инк. | Антитела к cd33 и иммуноконъюгаты |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| SI3189081T1 (sl) * | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Sredstva, ki se vežejo na CD123 in njihove uporabe |
| KR20180033502A (ko) * | 2015-06-12 | 2018-04-03 | 알렉터 엘엘씨 | 항-cd33 항체 및 그의 사용 방법 |
| EP3307779A2 (en) * | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| EP3589658A1 (en) | 2017-08-03 | 2020-01-08 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| WO2019164929A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting cd33, and use thereof |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
-
2018
- 2018-05-24 JO JOP/2019/0116A patent/JOP20190116A1/ar unknown
-
2019
- 2019-05-21 MA MA052771A patent/MA52771A/fr unknown
- 2019-05-21 JP JP2020564908A patent/JP2021524244A/ja active Pending
- 2019-05-21 AU AU2019274229A patent/AU2019274229A1/en active Pending
- 2019-05-21 US US16/418,420 patent/US11466082B2/en active Active
- 2019-05-21 SG SG11202011210TA patent/SG11202011210TA/en unknown
- 2019-05-21 MX MX2020012588A patent/MX2020012588A/es unknown
- 2019-05-21 CR CR20200567A patent/CR20200567A/es unknown
- 2019-05-21 CA CA3101270A patent/CA3101270A1/en active Pending
- 2019-05-21 WO PCT/IB2019/054182 patent/WO2019224711A2/en unknown
- 2019-05-21 KR KR1020207036865A patent/KR20210013156A/ko unknown
- 2019-05-21 CN CN201980034952.6A patent/CN112189022A/zh active Pending
- 2019-05-21 EP EP19737216.2A patent/EP3802606A2/en active Pending
- 2019-05-21 PE PE2020001885A patent/PE20210180A1/es unknown
- 2019-05-21 BR BR112020023357-9A patent/BR112020023357A2/pt unknown
- 2019-05-23 TW TW108117806A patent/TW202033551A/zh unknown
- 2019-05-24 UY UY0001038242A patent/UY38242A/es unknown
-
2020
- 2020-11-19 IL IL278844A patent/IL278844A/en unknown
- 2020-11-20 CL CL2020003028A patent/CL2020003028A1/es unknown
- 2020-11-23 NI NI202000088A patent/NI202000088A/es unknown
- 2020-11-23 EC ECSENADI202075198A patent/ECSP20075198A/es unknown
- 2020-11-23 PH PH12020552010A patent/PH12020552010A1/en unknown
- 2020-11-24 CO CONC2020/0014575A patent/CO2020014575A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019224711A5 (ru) | ||
| JP2018534933A5 (ru) | ||
| CN111944050B (zh) | 一种抗b7-h3抗体及其应用 | |
| JP2019146572A5 (ru) | ||
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| JP2019536740A5 (ru) | ||
| JP2019532056A5 (ru) | ||
| JPWO2019173420A5 (ru) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP2017529838A5 (ru) | ||
| JP2013534809A5 (ru) | ||
| JP2017510559A5 (ru) | ||
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| JP2013529904A5 (ru) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| JP2012532851A5 (ru) | ||
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2020522280A5 (ru) | ||
| JP2020522281A5 (ru) | ||
| JPWO2019173291A5 (ru) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2017521054A5 (ru) |